Table 4.

Summary of pre-clinical and clinical studies targeting HSP27 in OC.

sHSP	Targeting Compound	Effect or Mechanism	Used Cell Line/Model	Reference
HSP27	Paclitaxel	Suppression of HSP27 expression concomitant with cell growth inhibition	BG-1 ovarian cancer cells and HeLa uterine cancer cells	[198]
	Apatorsen (OGX-427)	The OGX-427, antisense inhibitor targeting HSP 27, caused marked reduction of CA-125 in a dose dependent manner	Phase I trial (OC patients)	[200]
	YangZheng XiaoJi (traditional Chinese herbal medicine)	Increasing sensitivity of cancer cells to chemotherapeutics via modulating phospho-HSP27 levels	A2780 and A2780-CP70, SKOV3 and COV504	[199]
	MT-4	Inhibition of tubulin polymerization and induction of apoptosis via hindering HSP27/caspase 3 interaction	A2780 and multidrug- resistant NCI-ADR/res human OC cell lines	[193]
CRYAB	None (CRYAB effect was proofed in vitro via overexpression)	Resistance of TRAIL- and cisplatin-induced apoptosis	OV-MZ-6 and HEY cells as well as tumor tissues from patients with OC	[189]